PAR 6.98% 20.0¢ paradigm biopharmaceuticals limited..

research reports and media, page-2867

  1. 384 Posts.
    lightbulb Created with Sketch. 58
    Looks like Kolon life science who is developing Invossa got a smack on the hand for misleading information about there product, and whats in it and the source of it.I wouldn't imagine this would sit very well with the FDA especially if it was intentional.
    If interested search(Kolon CEO arrested for mislabelling Invossa's ingredient).
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
20.0¢
Change
-0.015(6.98%)
Mkt cap ! $70.04M
Open High Low Value Volume
21.0¢ 21.0¢ 20.0¢ $201.6K 994.6K

Buyers (Bids)

No. Vol. Price($)
15 429247 20.0¢
 

Sellers (Offers)

Price($) Vol. No.
21.0¢ 13806 2
View Market Depth
Last trade - 16.10pm 04/10/2024 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.